G
Gabi Tarcic
Researcher at Weizmann Institute of Science
Publications - 35
Citations - 1746
Gabi Tarcic is an academic researcher from Weizmann Institute of Science. The author has contributed to research in topics: Cancer & Epidermal growth factor. The author has an hindex of 13, co-authored 31 publications receiving 1558 citations. Previous affiliations of Gabi Tarcic include Hebrew University of Jerusalem.
Papers
More filters
Journal ArticleDOI
A module of negative feedback regulators defines growth factor signaling.
Ido Amit,Ami Citri,Ami Citri,Tal Shay,Yiling Lu,Menachem Katz,Fan Zhang,Gabi Tarcic,Doris R. Siwak,John P. Lahad,Jasmine Jacob-Hirsch,Ninette Amariglio,Nora Vaisman,Eran Segal,Gideon Rechavi,Uri Alon,Gordon B. Mills,Eytan Domany,Yosef Yarden +18 more
TL;DR: This study addresses the dynamics of growth factor signaling through profiling of protein phosphorylation and gene expression, demonstrating the presence of a kinetically defined cluster of delayed early genes that function to attenuate the early events ofgrowth factor signaling.
Journal ArticleDOI
Corrigendum: The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.
Efrat Shema,Itay Tirosh,Yael Aylon,Jing Huang,Chaoyang Ye,Neta Moskovits,Nina Raver-Shapira,Neri Minsky,Neri Minsky,Judith Pirngruber,Gabi Tarcic,Pavla Hublarova,Lilach Moyal,Mali Gana-Weisz,Yosef Shiloh,Yossef Yarden,Steven A. Johnsen,Borivoj Vojtesek,Shelley L. Berger,Moshe Oren +19 more
TL;DR: RNF20 depletion augmented the transcriptional effects of epidermal growth factor, increased cell migration, and elicited transformation and tumorigenesis in tumors, and may be a putative tumor suppressor, acting through selective regulation of a distinct subset of genes.
Journal ArticleDOI
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
David S. Hong,Van K. Morris,Badi El Osta,Alexey V. Sorokin,Filip Janku,Siqing Fu,Michael J. Overman,Sarina Anne Piha-Paul,Vivek Subbiah,Bryan K. Kee,Apostolia Maria Tsimberidou,David R. Fogelman,Jorge Bellido,Imad Shureiqi,Helen J. Huang,Johnique T. Atkins,Gabi Tarcic,Nicolas Sommer,Richard B. Lanman,Funda Meric-Bernstam,Scott Kopetz +20 more
TL;DR: Vemurafenib, in combination with irinotecan and cetuximab, was well tolerated in patients with refractory, BRAF-mutated metastatic colorectal cancer, and both survival outcomes and response rates exceeded prior reports.
Journal ArticleDOI
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration
Menachem Katz,Ido Amit,Ami Citri,Tal Shay,Silvia Carvalho,Sara Lavi,Fernanda Milanezi,Ljuba Lyass,Ninette Amariglio,Jasmine Jacob-Hirsch,Nir Ben-Chetrit,Gabi Tarcic,Moshit Lindzen,Roi Avraham,Yi Chun Liao,Patricia Trusk,Asya Lyass,Gideon Rechavi,Neil L. Spector,Su Hao Lo,Fernando Schmitt,Sarah S. Bacus,Yosef Yarden +22 more
TL;DR: This article showed that EGF downregulates tensin-3 expression and concomitantly upregates cten, a tensin family member that lacks the actin-binding domain.
Journal ArticleDOI
An Unbiased Screen Identifies DEP-1 Tumor Suppressor as a Phosphatase Controlling EGFR Endocytosis
Gabi Tarcic,Shlomit Boguslavsky,Jean Wakim,Tai Kiuchi,Tai Kiuchi,Angela Liu,Felicia Reinitz,David Nathanson,Takamune Takahashi,Paul S. Mischel,Tony Ng,Yosef Yarden +11 more
TL;DR: EGFR and DEP-1 physically interact at the cell surface and maintain bidirectional enzyme-substrate interactions, which are relevant to their respective oncogenic and tumor-suppressive functions, and highlight the emerging roles of vesicular trafficking in malignant processes.